During the last session, Ginkgo Bioworks Holdings Inc (NYSE:DNA)’s traded shares were 1.31 million, with the beta value of the company hitting 1.17. At the end of the trading day, the stock’s price was $13.55, reflecting an intraday gain of 9.98% or $1.23. The 52-week high for the DNA share is $64.40, that puts it down -375.28 from that peak though still a striking 61.18% gain since the share price plummeted to a 52-week low of $5.26. The company’s market capitalization is $778.84M, and the average trade volume was 1.54 million shares over the past three months.
Ginkgo Bioworks Holdings Inc (DNA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.83. DNA has a Sell rating from 2 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.3.
Ginkgo Bioworks Holdings Inc (NYSE:DNA) trade information
Ginkgo Bioworks Holdings Inc (DNA) registered a 9.98% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 9.98% in intraday trading to $13.55, hitting a weekly high. The stock’s 5-day price performance is -0.95%, and it has moved by 58.29% in 30 days. Based on these gigs, the overall price performance for the year is -77.57%.
The consensus price target of analysts on Wall Street is $7, which implies a decrease of -93.57% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $7 and $7 respectively. As a result, DNA is trading at a premium of 48.34% off the target high and 48.34% off the low.
Ginkgo Bioworks Holdings Inc (DNA) estimates and forecasts
In the rating firms’ projections, revenue will decrease -9.45% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 44.43M as predicted by 5 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 44.24M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 34.76M and 37.94M respectively. In this case, analysts expect current quarter sales to grow by 27.83% and then jump by 16.60% in the coming quarter.
While earnings are projected to return 45.22% in 2025, the next five years will return 43.25% per annum.
DNA Dividends
Ginkgo Bioworks Holdings Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 138.96 million shares, is of VANGUARD GROUP INC’s that is approximately 6.9327% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $46.46 million.
